HVTN 303 |
HIV Vaccine |
I |
|
|
Men |
|
Planned |
Purpose 4/ HPTN 103 |
PrEP |
Open Label |
|
|
Injecting drug users |
Lenacapavir |
Planned |
PURPOSE 3/ HPTN 102 |
PrEP |
Open Label |
|
|
Men |
Lenacapavir , TDF/FTC (Truvada) |
Planned |
IAVI G003 |
HIV Vaccine |
I |
May 2022 |
South Africa, Rwanda |
Men, Women |
mRNA-1644 (eOD-GT8 60mer) |
Ongoing |
IAVI G001 |
HIV Vaccine |
Open Label |
June 2018 |
United States of America |
Men, Women |
|
Completed |
HPTN 074 |
PrEP, Treatment |
Open Label, III |
February 2015 |
Indonesia, Ukraine, Thailand |
HIV positive, Injecting drug users |
|
Completed |
HPTN 091 |
PrEP |
Open Label |
March 2021 |
United States of America, Brazil |
Men |
TAF/FTC (Descovy), TDF/FTC (Truvada) |
|
HPTN 096 |
General, PrEP, Treatment |
Open Label, Other |
April 2022 |
|
HIV positive, MSM |
|
Ongoing |
HPTN 078 |
General, Treatment |
Other |
June 2016 |
United States of America |
HIV positive, MSM |
|
Completed |
HPTN 094/ INTEGRA |
General, PrEP, Treatment |
Demo Project, Open Label |
June 2021 |
United States of America |
HIV positive, Injecting drug users, Men, Women |
|
Ongoing |
HVTN 908 |
HIV Vaccine |
Open Label |
July 2009 |
United States of America |
Men |
JS7 DNA Vaccine, MVA/HIV62 vaccine |
Completed |
HVTN 302 |
HIV Vaccine |
Open Label |
February 2022 |
United States of America |
Men, Women |
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA |
Ongoing |
HVTN 300 |
HIV Vaccine |
I |
May 2022 |
United States of America |
Men |
CH505TF |
Ongoing |
IPCAVD 010/ HPX1002 |
HIV Vaccine |
I |
March 2016 |
|
Men, Women |
Ad26.Mos.HIV, gp140 |
Completed |
PROMISE-EPI |
Combination Prevention |
Open Label |
December 2019 |
Burkina Faso, Zambia |
Women |
Lamivudine |
Ongoing |
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults |
Treatment |
I |
November 2018 |
United States of America |
Men |
Lenacapavir |
Completed |
CALIBRATE |
Combination Prevention |
Open Label, II |
November 2019 |
United States of America, Dominican Republic, Puerto Rico |
Men, Women |
F/TAF, Lenacapavir , tenofovir, emtricitabine |
|
PURPOSE 1 |
Combination Prevention |
III |
August 2021 |
South Africa |
Women |
F/TAF, Lenacapavir , F/TDF |
Ongoing |
CAPELLA |
Combination Prevention |
III, II |
November 2019 |
United States of America, France, Italy, South Africa, Spain, Thailand, Canada, Dominican Republic, Germany, Japan, Taiwan |
HIV positive, Men, Women |
Lenacapavir |
Ongoing |
PURPOSE 2 |
PrEP |
III |
June 2021 |
United States of America |
Men, MSM, Transgender men, Transgender women |
Lenacapavir , F/TDF |
Ongoing |